NYSEHealth CareHealth Care FacilitiesS&P MidCap 400
$137.54
-3.73 (-2.64%)
Close of Nov 06, 2026 · end-of-day data
EHC 8-K filings in 2026
Every material Form 8-K Encompass Health filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Encompass Health said its Sea Pines Rehabilitation Hospital in Melbourne, Florida, remains closed indefinitely after torrential rains on Nov. 1-2, 2026 caused flooding and substantial damage. The company reaffirmed its full-year 2026 guidance, which it said excludes closure-related costs and insurance proceeds from non-GAAP measures, but the closure removes a 90-bed facility from its operations while the joint venture evaluates repair or replacement options.
Sea Pines is a 90-bed hospital owned by a joint venture between Encompass Health and Holmes Regional Medical Center, a subsidiary of Health First.
For the first nine months of 2026, Sea Pines had net operating revenue of approximately $44 million and contributed approximately $14 million to Adjusted EBITDA.
Full-year 2026 guidance was reaffirmed: net operating revenue of $6,450 million to $6,500 million, Adjusted EBITDA of $1,395 million to $1,415 million, and adjusted EPS of $6.23 to $6.37.
All patients were evacuated safely, and the joint venture is in discussions with its partner on the path forward for reopening.
Encompass Health reported third-quarter 2026 net operating revenue of $1.6 billion, up 8.9% from a year earlier, and diluted earnings per share from continuing operations of $1.51, up from $1.24. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA and adjusted earnings per share, which gives shareholders a higher expected range for the year.
Q3 2026 net operating revenue was $1,609.5 million, up 8.9% from $1,477.5 million; Adjusted EBITDA was $346.6 million, up 15.5%.
Diluted EPS from continuing operations was $1.51 versus $1.24; adjusted EPS was $1.52 versus $1.23.
2026 adjusted EPS guidance rose to $6.23 to $6.37 from $6.02 to $6.25; Adjusted EBITDA guidance rose to $1,395 million to $1,415 million from $1,365 million to $1,395 million.
Management will discuss the results on an earnings call at 10:00 a.m. Eastern Time on Thursday, October 29, 2026.
Encompass Health reported second-quarter 2026 net operating revenue of $1.6 billion, up 9.6% from a year earlier, and adjusted earnings per share of $1.55, up 10.7%. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA and adjusted EPS, and increased its common stock repurchase authorization to $1 billion, which may matter to shareholders because it signals higher expected earnings and more capital returned to shareholders.
Q2 2026 net operating revenue was $1,597.4 million, up from $1,457.7 million, and Adjusted EBITDA was $348.0 million, up from $318.6 million.
Full-year 2026 adjusted EPS guidance was raised to $6.02 to $6.25 from $5.89 to $6.11; Adjusted EBITDA guidance was raised to $1,365 million to $1,395 million from $1,350 million to $1,380 million.
The board approved on July 23, 2026 an increase in the repurchase authorization to $1 billion; $145.8 million was repurchased year to date and about $188 million remained under the prior authorization as of June 30, 2026.
Adjusted free cash flow was $177.0 million in the quarter, down 4.8% from $185.9 million a year earlier.
Encompass Health completed a $500 million private offering of 5.875% senior notes due 2034 on May 29, 2026, with net proceeds of about $491.2 million. The company plans to use the proceeds, along with cash on hand, to redeem $400 million of its 4.500% notes due 2028 and repay $100 million on its revolving credit facility, which refinances part of its existing debt rather than adding a stated new use of funds.
Notes: $500 million principal, 5.875% annual interest, maturing June 1, 2034
Net proceeds of approximately $491.2 million after discounts and expenses
Plans to redeem $400 million of the $800 million 4.500% notes due 2028 and repay $100 million on the revolving credit facility
Computershare Trust Company is trustee under the indenture
Encompass Health priced a private offering of $500 million of 5.875% senior notes due 2034 at 100% of principal, with closing expected on or about May 29, 2026. The company plans to use the proceeds, together with cash on hand, to redeem $400 million of its 4.500% notes due 2028 at par and to repay $100 million under its revolving credit facility, which changes the mix of its debt but the filing does not state a figure for the effect on interest expense.
$500 million principal of 5.875% senior notes due 2034 priced at 100% of principal, announced May 14, 2026
Expected closing on or about May 29, 2026, subject to customary conditions; interest paid semiannually on June 1 and Dec. 1, starting Dec. 1, 2026
Proceeds plus cash on hand: $400 million to redeem 4.500% notes due 2028 (of $800 million outstanding) and $100 million to repay revolver borrowings
Encompass Health reported first-quarter 2026 net operating revenue of $1,586.6 million, up 9.0%, and diluted earnings per share from continuing operations of $1.77, up from $1.48 a year earlier. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and adjusted earnings per share, though adjusted free cash flow declined 12.9%.
Q1 2026 net operating revenue was $1,586.6 million versus $1,455.4 million, up 9.0%
Q1 2026 diluted EPS from continuing operations was $1.77 versus $1.48; adjusted EPS was $1.60 versus $1.37
Full-year 2026 guidance: net operating revenue raised to $6,375 million to $6,470 million; adjusted EPS raised to $5.89 to $6.11
Adjusted free cash flow was $193.8 million, down from $222.4 million, and included a $17.5 million pre-tax gain on the sale of Gamma Knife
Encompass Health entered a new $1 billion revolving credit facility with Truist Bank as administrative agent on March 9, 2026, and used it to repay in full the remaining amounts under its 2022 credit agreement with Barclays. The new facility matures March 9, 2031, rather than October 7, 2027, and carries slightly lower fees and relaxed limits on investments, debt, liens and restricted payments. The refinancing extends the company's borrowing terms and loosens some covenants, which matters to shareholders because it changes the company's debt structure and flexibility.
New $1 billion revolving credit facility dated March 9, 2026, with maturity on March 9, 2031
On March 9, 2026, $250.0 million was drawn on the revolver to retire the 2022 Credit Agreement balance
Covenants include minimum Interest Coverage Ratio of 3.00:1.00 and maximum Leverage Ratio of 4.50:1.00, except for a Significant Acquisition
Accordion feature allows increases of the greater of $1.4 billion or 100% of trailing four-quarter Adjusted Consolidated EBITDA, subject to a 3.50:1.00 Senior Secured Leverage Ratio test
Encompass Health reported fourth-quarter 2025 net operating revenue of $1.54 billion, up 9.9% from a year earlier, and diluted earnings per share from continuing operations of $1.42, up from $1.18. The company also issued 2026 guidance, including adjusted earnings per share of $5.81 to $6.10, which gives shareholders a company-set benchmark for the year ahead.
Q4 2025 net operating revenue was $1.54 billion, up 9.9% from $1.41 billion in Q4 2024.
Q4 2025 adjusted EBITDA was $335.6 million, up 15.9%; adjusted EPS was $1.46, up 24.8%.
2026 guidance: net operating revenue of $6.365 billion to $6.465 billion and adjusted EBITDA of $1.340 billion to $1.380 billion.
The company will hold its earnings call at 10:00 a.m. Eastern Time on February 6, 2026.
Encompass Health's board elected Cain A. Hayes as a director on January 30, 2026, and the company announced the appointment on February 2, 2026. The board has determined Hayes is independent under NYSE listing standards, and he has not yet been named to a committee. The filing reports no financial results or guidance, so the change is a board-composition update rather than a direct financial event.
Board elected Cain A. Hayes as director on January 30, 2026, on the recommendation of the Nominating/Corporate Governance Committee
Board has determined Hayes is independent under NYSE listing standards; no committee assignment yet
Hayes retired as president and CEO of Point32Health, Inc. in 2024 and previously led Gateway Health Plan, Inc.
Compensation follows the standard nonemployee director practices described in the April 1, 2025 proxy statement
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Encompass Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →